Position in GRFS
as of Jun 30, 2026
· filed Jul 2, 2026
Position Value
$49,262
+$8,232 QoQ
Shares Held
6,958
+36.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#112
of 164 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Versant Capital Management, Inc holds $22,172,877 across 17 Drug Manufacturers - General names. GRFS ranks #15 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
3,562 | $4,272,370 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
73,361 | $4,227,060 | |
| 3 | JNJ |
Johnson & Johnson
|
13,834 | $3,513,420 | |
| 4 | ABBV |
AbbVie Inc.
|
6,899 | $1,736,064 | |
| 5 | NVS |
Novartis AG
|
10,771 | $1,688,031 | |
| 6 | MRK |
Merck & Co., Inc.
|
12,085 | $1,552,922 | |
| 7 | AZN |
Astrazeneca PLC
|
7,263 | $1,377,210 | |
| 8 | AMGN |
Amgen Inc
|
1,980 | $716,997 |
All Filings in GRFS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $49,262 | 6,958 | Shares | Sole | 2026-07-02 | |
| 2026-03-31 | $41,030 | 5,116 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $29,097 | 3,112 | Shares | Sole | 2026-01-08 | |
| 2025-09-30 | $55,756 | 5,598 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $36,286 | 4,014 | Shares | Sole | 2025-07-07 | |
| 2025-03-31 | $27,814 | 3,912 | Shares | Sole | 2025-04-03 | |
| No filing history on record for this holder in this stock. | ||||||